Ankylosing Spondylitis
📧 Sign up to get email alerts when something new happens for Ankylosing Spondylitis.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-27EMA Authorised: Hulio (adalimumab) — Biosimilar Collaborations Ireland Limited
EMA authorised Hulio (adalimumab) biosimilar with approvals across multiple inflammatory indications.
-
EMA approval · 2026-08-24EMA Authorised: Yuflyma (adalimumab) — Celltrion Healthcare Hungary Kft.
EMA authorised Yuflyma (adalimumab) for multiple inflammatory diseases including rheumatoid arthritis and Crohn's disease.
-
EMA approval · 2026-08-18EMA Authorised: Amgevita (adalimumab) — Amgen Europe B.V.
Amgevita (adalimumab) by Amgen Europe B.V. has been authorised by the EMA for multiple inflammatory diseases including arthritis, psoriatic …
-
CLINICAL_TRIALS trial_result · 2026-08-14Clinical Trial Update: A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis [Phase 3]
Phase 3 trial evaluating long-term safety, tolerability, and efficacy of bimekizumab in active axial spondyloarthritis including ankylosing …
-
EMA approval · 2026-08-06EMA Authorised: Idacio (adalimumab) — Fresenius Kabi Deutschland GmbH
European Medicines Agency authorises Idacio (adalimumab) from Fresenius Kabi Deutschland for multiple inflammatory diseases including rheuma…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-08-05EMA Authorised: Humira (adalimumab) — AbbVie Deutschland GmbH & Co. KG
EMA authorises Humira (adalimumab) for multiple inflammatory diseases across indications, confirming market authorization.
-
EMA approval · 2026-07-30EMA Authorised: Hulio (adalimumab) — Biosimilar Collaborations Ireland Limited
Biosimilar adalimumab (Hulio) has been authorised by EMA for multiple indications including hidradenitis suppurativa, psoriasis, uveitis, rh…
-
EMA approval · 2026-07-17EMA Authorised: Hukyndra (adalimumab) — Stada Arzneimittel AG
EU authorization of Hukyndra (adalimumab) by Stada Arzneimittel AG for multiple inflammatory diseases including rheumatoid arthritis and inf…
-
CLINICAL_TRIALS trial_result · 2026-07-17Clinical Trial Update: A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis [Phase 3]
Phase 3 trial update evaluating long-term safety, tolerability, and efficacy of bimekizumab in active axial spondyloarthritis including anky…
-
EMA approval · 2026-07-15EMA Authorised: Rinvoq (upadacitinib) — AbbVie Deutschland GmbH & Co. KG
Rinvoq (upadacitinib) has been authorised by the EMA for multiple inflammatory diseases including rheumatoid arthritis, psoriatic arthritis,…
-
EMA approval · 2026-07-13EMA Authorised: Libmyris (adalimumab) — Stada Arzneimittel AG
Authorised status for Libmyris (adalimumab) by Stada Arzneimittel AG for multiple inflammatory and autoimmune diseases.
-
EMA approval · 2026-07-13EMA Authorised: Idacio (adalimumab) — Fresenius Kabi Deutschland GmbH
European Medicines Agency authorises Idacio (adalimumab) for multiple inflammatory diseases, expanding the portfolio under Fresenius Kabi De…
-
EMA approval · 2026-07-01EMA Authorised: Erelzi (etanercept) — Sandoz GmbH
Authorised status for Erelzi (etanercept) by Sandoz GmbH, expanding access to therapy for multiple inflammatory arthritis conditions.
-
EMA approval · 2026-06-12EMA Authorised: Fubelv — Biosimilar Collaborations Ireland Limited
EMA has authorised Fubelv as a biosimilar, with indications across various inflammatory arthritis and psoriasis conditions.
-
EMA approval · 2026-06-05EMA Authorised: Idacio (adalimumab) — Fresenius Kabi Deutschland GmbH
The EMA has authorised Idacio (adalimumab) by Fresenius Kabi Deutschland GmbH for multiple inflammatory diseases, marking a new approved pro…
-
CLINICAL_TRIALS trial_result · 2026-04-24Clinical Trial Update: A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis [Phase 3]
Phase 3 trial evaluating the long-term safety, tolerability, and efficacy of bimekizumab in active axial spondyloarthritis, including ankylo…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Frequency and Complications of Major Orthopedic Procedures in Medicare Beneficiaries
A NIAMS-sponsored clinical trial update examines the frequency and complications of major orthopedic procedures among Medicare beneficiaries…
-
EMA approval · 2026-04-23EMA Authorised: Remsima (infliximab) — Celltrion Healthcare Hungary Kft.
EMA authorised Remsima (infliximab) from Celltrion Healthcare Hungary Kft. for multiple inflammatory diseases including rheumatoid arthritis…
-
EMA approval · 2026-04-23EMA Authorised: Amgevita (adalimumab) — Amgen Europe B.V.
EMA has authorised Amgevita (adalimumab) by Amgen Europe B.V., a biosimilar of adalimumab, for multiple inflammatory diseases including rheu…
-
CLINICAL_TRIALS withdrawal · 2026-04-21Clinical Trial Update: Clinical Trial Study on the Improved New Method of Acupotomy for AS [NA]
A clinical trial evaluating an improved acupotomy method for ankylosing spondylitis has been withdrawn.
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: A Phase I/Ⅱ Clinical Trial for Umbilical Cord Mesenchymal Stem Cells (UC-MSC) in the Treatment of Ankylosing Spondylitis [Phase 1, Phase 2]
A Phase I/II clinical trial evaluating Umbilical Cord Mesenchymal Stem Cells for the treatment of Ankylosing Spondylitis, with status NOT_YE…
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: Oxidative Stress in Autoimmune Rheumatic Diseases
A University of Thessaly–sponsored clinical trial is recruiting to study oxidative stress in autoimmune rheumatic diseases, including rheuma…
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: Natural History and Development of Spondyloarthritis
This clinical trial update describes NIAMS-sponsored study on the natural history and development of spondyloarthritis. The study covers art…
-
CLINICAL_TRIALS trial_result · 2026-04-16Clinical Trial Update: Progression of Spinal Fusion in Ankylosing Spondylitis
A completed clinical trial update assessing the progression of spinal fusion in patients with Ankylosing Spondylitis.
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: The Disease Progression of Chinese Axial Spondyloarthritis in a Real-word Cohort Study
A real-world cohort study in China is investigating disease progression in axial spondyloarthritis, including ankylosing spondylitis, and is…